Immuno-Oncology

The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

June 27th 2025

Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving immunotherapy, according to new research.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

cancer vaccine | Image credit: IO Biotech
From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results

May 3rd 2025

Round FDA approval stamp in blue ink | Image Credit: © Surendra - stock.adobe.com
FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

March 31st 2025

Travis Osterman, DO, MS, FAMIA, FASCO
Leveraging AI to Optimize Precision Immunotherapy at Vanderbilt

October 25th 2024

More News

Pembrolizumab Gets Priority Review for Merkel Cell Carcinoma
September 5th 2018

Pembrolizumab Gets Priority Review for Merkel Cell Carcinoma

Mary Caffrey
FDA's designation is based on phase 2 data presented earlier this year at the American Society of Clinical Oncology Annual Meeting.
Ipilimumab, Opdivo Provides Durable Response in Melanoma Brain Metastases
August 31st 2018

Ipilimumab, Opdivo Provides Durable Response in Melanoma Brain Metastases

Samantha DiGrande
A study recently found that an immunotherapy combination treatment of ipilimumab (Yervoy) and nivolumab (Opdivo) shrank melanoma that had spread to the brain in more than half of participants.
UK Knocks Down Yescarta as CAR T Therapy Gains European Authorization
August 28th 2018

UK Knocks Down Yescarta as CAR T Therapy Gains European Authorization

Samantha DiGrande
Only 1 day after the European Commission approved CAR T-cell therapies, the National Institute for Health and Care Excellence deemed the treatment too expensive to justify on Britain's state-funded health service.
Utilizing Bioinformatics to Determine a Patient's Response to Immunotherapy
August 24th 2018

Utilizing Bioinformatics to Determine a Patient's Response to Immunotherapy

Samantha DiGrande
A recent study at Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy discovered a new way to use bioinformatics to determine how a patient’s immune system responds to immunotherapy.
MEDCAC Panel Mostly Endorses PROs for CAR T Therapies
August 22nd 2018

MEDCAC Panel Mostly Endorses PROs for CAR T Therapies

Allison Inserro
During a meeting of the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC), panelists heard from chimeric antigen receptor (CAR) T therapy drug makers, health researchers, and policy makers, and mostly endorsed including patient-reported outcomes (PROs) in its final national coverage analysis decision, expected next year.
CAR T Signaling Differences Could Point the Way to More Targeted Treatments, Study Says
August 21st 2018

CAR T Signaling Differences Could Point the Way to More Targeted Treatments, Study Says

Allison Inserro
The first chimeric antigen receptor (CAR) T-cell therapy was approved just a year ago, changing the face of treatment for certain types of leukemias and lymphomas but carrying with it the downsides of toxicity and cost. A year later, scientists from a major cancer center said that they’ve made headway to discovering more about the T-cell signaling patterns and that understanding more about the biological pathways could help design the next generation of CAR-T treatments.
Opdivo Approved to Treat Metastatic SCLC
August 17th 2018

Opdivo Approved to Treat Metastatic SCLC

Samantha DiGrande
Announced today, Bristol-Myers Squibb’s nivolumab (Opdivo) has received FDA approval as the first immuno-oncology treatment for patients with metastatic small-cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least 1 other line of treatment.
Site Logo
August 17th 2018

Many Questions to Ask in Setting National Coverage for CAR T Therapies

Allison Inserro
Next week, a CMS committee will hold a day-long meeting to discuss a national coverage determination (NCD) for chimeric antigen receptor (CAR) T-cell immunotherapies, and in Thursday’s New England Journal of Medicine, Peter B. Bach, MD, MAPP, reviewed several strategies open to CMS as it continues to try to determine how to pay for CAR T.
Is the Rapid Uptake of Immunotherapies Sacrificing Patient Safety?
August 14th 2018

Is the Rapid Uptake of Immunotherapies Sacrificing Patient Safety?

Samantha DiGrande
In a study published in JAMA Oncology, researchers found that a majority of patients eligible for immune checkpoint inhibitors started to receive the treatment within a few months of the drugs approval.
This Week in Managed Care: August 10, 2018
August 10th 2018

This Week in Managed Care: August 10, 2018

This week, the top managed care stories included, CMS allowing step therapy in Medicare Advantage plans in a bid to allow for drug price negotiation; larger practices with more resources, technology and care management processes have higher readmission rates than smaller practices; studies find that empagliflozin also reduces liver fat in patients with diabetes and nonalcoholic fatty liver disease.
MD Anderson, PALISI Jointly Develop Pediatric Guidelines for CAR T-Cell Therapy
August 9th 2018

MD Anderson, PALISI Jointly Develop Pediatric Guidelines for CAR T-Cell Therapy

Samantha DiGrande
Researchers from the University of Texas MD Anderson Cancer Center, along with the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI), recently published guidelines in Nature Reviews Clinical Oncology for the management of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia.
Liquid Biopsy Identifies Patients More Likely to Benefit From Immunotherapy in NSCLC
August 7th 2018

Liquid Biopsy Identifies Patients More Likely to Benefit From Immunotherapy in NSCLC

Samantha DiGrande
A blood-based test to assess tumor mutational burden (TMB) was recently discovered as being able to accurately identify patients with non–small cell lung cancer (NSCLC) who could benefit from checkpoint inhibitor treatment. The study, conducted by researchers at UC Davis, Genentech, and Foundation Medicine, was published in Nature Medicine.
FDA Accepts First Allogeneic CAR T-Cell Therapy Trial
August 4th 2018

FDA Accepts First Allogeneic CAR T-Cell Therapy Trial

Samantha DiGrande
Celyad, a biopharmaceutical company that focuses on the development of chimeric antigen receptor (CAR) T-cell therapies, recently announced that the FDA has accepted its Investigational New Drug (IND) application for CYAD-101, the first non–gene-edited allogeneic clinical program.
Opdivo Approved for Adjuvant Treatment of Melanoma in European Union
August 2nd 2018

Opdivo Approved for Adjuvant Treatment of Melanoma in European Union

Samantha DiGrande
Bristol-Myers Squibb recently announced that the European Commission has approved nivolumab (Opdivo) for the adjuvant treatment of adult patients with melanoma that have lymph node involvement or metastatic disease and who have undergone complete resection.
Cytokine "Backpacks" for T Cells Increase Immune Response in Solid Tumors
July 27th 2018

Cytokine "Backpacks" for T Cells Increase Immune Response in Solid Tumors

Samantha DiGrande
A new study published in Nature Biotechnology found that by attaching a kind of cytokine “backpack” to T-cells through the use of a nanoparticle gel enhanced their efficacy in treating tumors in mice.
Pembrolizumab Meets Primary End Point in Phase 3 Head and Neck Cancer Trial
July 25th 2018

Pembrolizumab Meets Primary End Point in Phase 3 Head and Neck Cancer Trial

Samantha DiGrande
KEYNOTE-048, a phase 3 trial studying pembrolizumab (Keytruda) as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors overexpress PD-L1, has met a primary end point of overall survival.
Men With Advanced Cancers Respond Better Than Women to Immune Checkpoint Inhibitors
July 20th 2018

Men With Advanced Cancers Respond Better Than Women to Immune Checkpoint Inhibitors

Samantha DiGrande
A recent systematic review and meta-analysis published in The Lancet Oncology found that men with advanced cancers respond better than women to treatment with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors.
Tecentriq–Avastin Combination Earns Breakthrough Therapy Designation for Liver Cancer
July 18th 2018

Tecentriq–Avastin Combination Earns Breakthrough Therapy Designation for Liver Cancer

Samantha DiGrande
Genentech announced yesterday that the FDA has granted Breakthrough Therapy Designation to atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) as a first-line treatment for patients with the most common form of liver cancer, advanced or metastatic hepatocellular carcinoma (HCC).
Sequencing Therapy in NSCLC
July 18th 2018

Sequencing Therapy in NSCLC

Using Antiangiogenic Therapy in NSCLC in the Future
July 18th 2018

Using Antiangiogenic Therapy in NSCLC in the Future

Antiangiogenic Therapy in NSCLC: Addressing the Unknown
July 18th 2018

Antiangiogenic Therapy in NSCLC: Addressing the Unknown

Necitumumab in Squamous NSCLC
July 18th 2018

Necitumumab in Squamous NSCLC

Rationale for Ramucirumab in NSCLC
July 18th 2018

Rationale for Ramucirumab in NSCLC

Pembrolizumab in First-Line Nonsquamous NSCLC
July 18th 2018

Pembrolizumab in First-Line Nonsquamous NSCLC

Antiangiogenic Therapy in NSCLC
July 18th 2018

Antiangiogenic Therapy in NSCLC

Breakthroughs in Treating NSCLC
July 18th 2018

Breakthroughs in Treating NSCLC

Key Points From the REVEL Trial in NSCLC
July 18th 2018

Key Points From the REVEL Trial in NSCLC

Considerations for Antiangiogenic Therapy in NSCLC
July 18th 2018

Considerations for Antiangiogenic Therapy in NSCLC

Evidence for Immunotherapy in Frontline NSCLC
July 18th 2018

Evidence for Immunotherapy in Frontline NSCLC

Future Use of Antiangiogenic Agents in NSCLC
July 18th 2018

Future Use of Antiangiogenic Agents in NSCLC

<1
...
789101112131415>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo